We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this study, Cardiology Today Intervention Section ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — The PCSK9 inhibitor alirocumab was cost effective up to $6,319 per year at a willingness to pay ...

Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast ...

Experts discuss lessons learned from implementing lipid-lowering therapy recommendations and explore the role value-based care models may play in successfully adopting the National Lipid Association’s ...